Alprazolam: Effects on Sleep and Withdrawal Phenomena

Anthony Kales, Edward Bixler, Antonio Vela‐Bueno, Constantin R. Soldatos, Rocco L. Manfredi

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Alprazolam was evaluated in chronic insomniacs in a 1‐mg bedtime dose. The 16‐night sleep laboratory protocol included four placebo‐baseline nights followed by seven nights of drug administration and five placebo‐withdrawal nights. On the first three drug nights (nights 5 to 7), the drug was highly effective in inducing and maintaining sleep with this short‐term use. By the end of the one week of administration (nights 9 to 11), however, the drug had lost about 40% of its efficacy. During drug use, one subject reported some difficulty in controlling expression of inappropriate emotions when interacting with others, which suggested the presence of disinhibition. On the third night following drug termination, there was a significant increase in sleep difficulty above baseline levels (rebound insomnia). This worsening was of comparable magnitude to the peak improvement of sleep with drug administration. Thus, the clinical utility of alprazolam when administered to insomniac patients appears to be limited because of a relatively rapid development of tolerance and possible disinhibitory reactions during drug use and the occurrence of rebound insomnia following withdrawal. 1987 American College of Clinical Pharmacology

Original languageEnglish (US)
Pages (from-to)508-515
Number of pages8
JournalThe Journal of Clinical Pharmacology
Volume27
Issue number7
DOIs
StatePublished - Jan 1 1987

Fingerprint

Alprazolam
Sleep
Pharmaceutical Preparations
Sleep Initiation and Maintenance Disorders
Clinical Pharmacology
Emotions

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Kales, A., Bixler, E., Vela‐Bueno, A., Soldatos, C. R., & Manfredi, R. L. (1987). Alprazolam: Effects on Sleep and Withdrawal Phenomena. The Journal of Clinical Pharmacology, 27(7), 508-515. https://doi.org/10.1002/j.1552-4604.1987.tb03058.x
Kales, Anthony ; Bixler, Edward ; Vela‐Bueno, Antonio ; Soldatos, Constantin R. ; Manfredi, Rocco L. / Alprazolam : Effects on Sleep and Withdrawal Phenomena. In: The Journal of Clinical Pharmacology. 1987 ; Vol. 27, No. 7. pp. 508-515.
@article{c6a63f8f4ca84e4f9640e94373ee0496,
title = "Alprazolam: Effects on Sleep and Withdrawal Phenomena",
abstract = "Alprazolam was evaluated in chronic insomniacs in a 1‐mg bedtime dose. The 16‐night sleep laboratory protocol included four placebo‐baseline nights followed by seven nights of drug administration and five placebo‐withdrawal nights. On the first three drug nights (nights 5 to 7), the drug was highly effective in inducing and maintaining sleep with this short‐term use. By the end of the one week of administration (nights 9 to 11), however, the drug had lost about 40{\%} of its efficacy. During drug use, one subject reported some difficulty in controlling expression of inappropriate emotions when interacting with others, which suggested the presence of disinhibition. On the third night following drug termination, there was a significant increase in sleep difficulty above baseline levels (rebound insomnia). This worsening was of comparable magnitude to the peak improvement of sleep with drug administration. Thus, the clinical utility of alprazolam when administered to insomniac patients appears to be limited because of a relatively rapid development of tolerance and possible disinhibitory reactions during drug use and the occurrence of rebound insomnia following withdrawal. 1987 American College of Clinical Pharmacology",
author = "Anthony Kales and Edward Bixler and Antonio Vela‐Bueno and Soldatos, {Constantin R.} and Manfredi, {Rocco L.}",
year = "1987",
month = "1",
day = "1",
doi = "10.1002/j.1552-4604.1987.tb03058.x",
language = "English (US)",
volume = "27",
pages = "508--515",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "7",

}

Kales, A, Bixler, E, Vela‐Bueno, A, Soldatos, CR & Manfredi, RL 1987, 'Alprazolam: Effects on Sleep and Withdrawal Phenomena', The Journal of Clinical Pharmacology, vol. 27, no. 7, pp. 508-515. https://doi.org/10.1002/j.1552-4604.1987.tb03058.x

Alprazolam : Effects on Sleep and Withdrawal Phenomena. / Kales, Anthony; Bixler, Edward; Vela‐Bueno, Antonio; Soldatos, Constantin R.; Manfredi, Rocco L.

In: The Journal of Clinical Pharmacology, Vol. 27, No. 7, 01.01.1987, p. 508-515.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Alprazolam

T2 - Effects on Sleep and Withdrawal Phenomena

AU - Kales, Anthony

AU - Bixler, Edward

AU - Vela‐Bueno, Antonio

AU - Soldatos, Constantin R.

AU - Manfredi, Rocco L.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Alprazolam was evaluated in chronic insomniacs in a 1‐mg bedtime dose. The 16‐night sleep laboratory protocol included four placebo‐baseline nights followed by seven nights of drug administration and five placebo‐withdrawal nights. On the first three drug nights (nights 5 to 7), the drug was highly effective in inducing and maintaining sleep with this short‐term use. By the end of the one week of administration (nights 9 to 11), however, the drug had lost about 40% of its efficacy. During drug use, one subject reported some difficulty in controlling expression of inappropriate emotions when interacting with others, which suggested the presence of disinhibition. On the third night following drug termination, there was a significant increase in sleep difficulty above baseline levels (rebound insomnia). This worsening was of comparable magnitude to the peak improvement of sleep with drug administration. Thus, the clinical utility of alprazolam when administered to insomniac patients appears to be limited because of a relatively rapid development of tolerance and possible disinhibitory reactions during drug use and the occurrence of rebound insomnia following withdrawal. 1987 American College of Clinical Pharmacology

AB - Alprazolam was evaluated in chronic insomniacs in a 1‐mg bedtime dose. The 16‐night sleep laboratory protocol included four placebo‐baseline nights followed by seven nights of drug administration and five placebo‐withdrawal nights. On the first three drug nights (nights 5 to 7), the drug was highly effective in inducing and maintaining sleep with this short‐term use. By the end of the one week of administration (nights 9 to 11), however, the drug had lost about 40% of its efficacy. During drug use, one subject reported some difficulty in controlling expression of inappropriate emotions when interacting with others, which suggested the presence of disinhibition. On the third night following drug termination, there was a significant increase in sleep difficulty above baseline levels (rebound insomnia). This worsening was of comparable magnitude to the peak improvement of sleep with drug administration. Thus, the clinical utility of alprazolam when administered to insomniac patients appears to be limited because of a relatively rapid development of tolerance and possible disinhibitory reactions during drug use and the occurrence of rebound insomnia following withdrawal. 1987 American College of Clinical Pharmacology

UR - http://www.scopus.com/inward/record.url?scp=0023230215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023230215&partnerID=8YFLogxK

U2 - 10.1002/j.1552-4604.1987.tb03058.x

DO - 10.1002/j.1552-4604.1987.tb03058.x

M3 - Article

C2 - 3655003

AN - SCOPUS:0023230215

VL - 27

SP - 508

EP - 515

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 7

ER -